← Search & browse all drugs

pipenzolate

A03AB14

Forms & Strengths

Pipenzolate bromide: Oral tablet (5 mg)
Pipenzolate bromide: Oral drops or elixir formulations (availability varies by region)

Adult Dosing

Peptic ulcer disease and gastrointestinal hypermotility: 5 mg orally 3 times daily, adjusted according to patient response and tolerance
Maximum recommended daily dose: Typically 15 mg to 30 mg divided into 3 to 4 doses

Pediatric Dosing

Safety and efficacy in pediatric patients have not been established; use is generally not recommended

Indications

Adjunctive therapy in the treatment of peptic ulcer disease
Management of gastrointestinal hypermotility and hypersecretion disorders

Mechanism of Action

Synthetic quaternary ammonium anticholinergic agent
Competitively blocks acetylcholine at muscarinic receptors on gastrointestinal smooth muscle, secretory cells, and the enteric nervous system
Reduces gastric acid secretion and gastrointestinal motility

Contraindications

Hypersensitivity to pipenzolate or other anticholinergic agents
Narrow-angle glaucoma
Gastrointestinal obstruction, paralytic ileus, or toxic megacolon
Severe ulcerative colitis or myasthenia gravis
Obstructive uropathy (e.g., prostatic hypertrophy with urinary retention)

Adverse Reactions

Xerostomia (dry mouth)
Blurred vision, mydriasis, and cycloplegia
Constipation and urinary retention
Tachycardia and palpitations
Dizziness, drowsiness, and headache
Reduced sweating leading to potential heat intolerance

Drug Interactions

Amantadine, anti-parkinsonism drugs, and tricyclic antidepressants may potentiate anticholinergic side effects
Antacids may decrease absorption of anticholinergic agents; administer separately
May antagonize the gastrointestinal motility effects of prokinetic agents such as metoclopramide or cisapride

Curated Content: Needs Vetting Before Put to Clinical Use